Edition:
United Kingdom

Charles River Laboratories International Inc (CRL.N)

CRL.N on New York Stock Exchange

105.80USD
22 Jan 2018
Change (% chg)

$-2.09 (-1.94%)
Prev Close
$107.89
Open
$104.40
Day's High
$106.42
Day's Low
$104.40
Volume
105,909
Avg. Vol
95,207
52-wk High
$119.03
52-wk Low
$77.65

Latest Key Developments (Source: Significant Developments)

Charles River Laboratories Acquires KWS Biotest for GBP 15 Mln
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES ACQUIRES KWS BIOTEST.CHARLES RIVER LABORATORIES ACQUIRES KWS BIOTEST.CHARLES RIVER LABORATORIES INTERNATIONAL INC - PURCHASE PRICE WAS APPROXIMATELY £15 MILLION IN CASH.CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍ TRANSACTION INCLUDES A POTENTIAL ADDITIONAL PAYMENT OF UP TO £3 MILLION BASED ON FUTURE PERFORMANCE​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - TRANSACTION IS NOT EXPECTED TO BE MATERIAL TO 2018 GAAP OR NON-GAAP RESULTS FROM OPERATIONS.CHARLES RIVER LABORATORIES INTERNATIONAL INC - TRANSACTION IS NOT EXPECTED TO BE MATERIAL TO 2018 GAAP OR NON-GAAP RESULTS FROM OPERATIONS.  Full Article

Charles River Laboratories Says New Tax Legislation Expected To Be Effectively Neutral To Co's GAAP, Non-GAAP EPS In 2018
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES SAYS NEW TAX LEGISLATION EXPECTED TO BE EFFECTIVELY NEUTRAL TO CO'S GAAP AND NON-GAAP EPS IN 2018 - SEC FILING.  Full Article

Charles River Laboratories reports Q3 non-GAAP EPS of $1.30
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Charles River Laboratories International Inc ::Updates 2017 guidance​.Announces third-quarter 2017 results from continuing operations.Q3 non-GAAP earnings per share $1.30.Q3 GAAP earnings per share $1.09.Q3 revenue $464.2 million versus I/B/E/S view $458.7 million.Q3 earnings per share view $1.22 -- Thomson Reuters I/B/E/S.Sees ‍2017 revenue growth, reported 9.75 percent - 10.5 percent​.Sees ‍2017 non-GAAP EPS estimate $5.08 - $5.18​.Sees ‍2017 GAAP EPS estimate $3.95 - $4.05​.FY2017 earnings per share view $5.10, revenue view $1.85 billion -- Thomson Reuters I/B/E/S.  Full Article

Charles River announces expansion of in vitro oncology services
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Charles River Laboratories International Inc :Charles River announces expansion of in vitro oncology services.Charles River Laboratories International Inc says partnership with InSphero AG, supplier of 3D solutions for in vitro drug discovery and development​.Charles River Laboratories International Inc - ‍through partnership, co will license its collection of patient-derived xenograft tumors to InSphero​.  Full Article

Charles River Laboratories reports Q4 GAAP earnings per share $0.93
Tuesday, 14 Feb 2017 

Charles River Laboratories International Inc : Charles River Laboratories announces fourth-quarter and full-year 2016 results from continuing operations and provides 2017 guidance . Q4 non-GAAP earnings per share $1.21 . Q4 GAAP earnings per share $0.93 . Q4 revenue $466.8 million versus I/B/E/S view $441.6 million . Q4 earnings per share view $1.11 -- Thomson Reuters I/B/E/S . Charles River Laboratories International Inc - Sees FY revenue growth from continuing operations between 7.5% - 9.0% . Charles River Laboratories International Inc - Sees FY GAAP EPS estimate from continuing operations between $4.33-$4.43 . Sees 2017 revenue growth, organic 7.0% - 8.5% . Charles River Laboratories International Inc - sees FY non-GAAP EPS estimate from continuing operations between $5.00 - $5.10 .FY2017 earnings per share view $5.05, revenue view $1.83 billion -- Thomson Reuters I/B/E/S.  Full Article

Charles River Labs says acquires Agilux Labs for $64 mln
Wednesday, 28 Sep 2016 

Charles River Laboratories International Inc : Charles river laboratories acquires Agilux Laboratories, Inc . Deal for $64 million . Says acquisition is expected to be neutral to Charles River's non-gaap earnings per share in q4 of 2016 . Agilux will be reported as part of charles river's discovery and safety assessment (dsa) segment . Purchase price was approximately $64 million in cash, . Agilux is expected to generate full-year revenue of $27 million in 2016 .Acquisition is expected to be slightly accretive to non-gaap earnings per share in 2017.  Full Article

Charles River Labs Q2 earnings per share $0.73
Wednesday, 3 Aug 2016 

Charles River Laboratories International Inc : Quarter 2016 results from continuing operations . Q2 gaap earnings per share $0.73 from continuing operations . Q2 earnings per share view $1.10 -- Thomson Reuters I/B/E/S . Q2 non-gaap earnings per share $1.20 . Q2 revenue $434.1 million versus i/b/e/s view $425.1 million . Q2 gaap earnings per share $0.73 . Sees 2016 gaap eps of $3.15-$3.25 . 2016 non-gaap eps estimate of $4.40 - $4.50 . 2016 revenue guidance range has been raised by 1% . Sees 2016 revenue growth on reported basis of 20% - 23.5% .Fy2016 earnings per share view $4.39, revenue view $1.65 billion -- Thomson Reuters I/B/E/S.  Full Article

Charles River Laboratories International Inc reaffirms FY 2016 revenue guidance; increases FY 2016 EPS guidance
Wednesday, 4 May 2016 

Charles River Laboratories International Inc:Reaffirming its revenue growth guidance for FY 2016, including contribution from WIL Research.Increases its non-GAAP earnings per share guidance for 2016 to primarily reflect first-quarter performance, better-than-expected operating margin improvement in the RMS segment, and the inclusion of WIL Research from April 4, 2016.Increases guidance for FY 2016 non-GAAP earnings per share to a range of $4.32 to $4.45.  Full Article

Charles River Laboratories International Inc and BioMotiv enter into strategic partnership
Wednesday, 13 Apr 2016 

Charles River Laboratories International Inc:Has entered into a strategic partnership with BioMotiv LLC.Charles River has committed to invest up to $10 million in BioMotiv.Says through agreement, Charles River will be preferred drug discovery and preclinical development partner for BioMotiv's portfolio of technologies and companies.  Full Article